Literature DB >> 2597212

Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy.

M E Weinblatt1, P Fraser.   

Abstract

Retrospective analysis of 23 rheumatoid arthritis patients receiving low-dose methotrexate (MTX) demonstrated an association between the mean corpuscular volume (MCV) and hematologic toxicity. All 6 patients who developed hematologic toxicity were folate deficient, and 4 of 6 had marked macrocytosis. Furthermore, the mean MCV of the patients who developed toxicity was significantly higher than that of the controls without toxicity (P less than 0.02). This difference in MCV was associated with an increased probability of developing toxicity with time (P less than 0.005). These results suggest that sustained elevation in the MCV may be a predictor of impending hematologic toxicity due to folate depletion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2597212     DOI: 10.1002/anr.1780321214

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Pharmacological management of juvenile rheumatoid arthritis.

Authors:  C D Rose; R A Doughty
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

3.  [Reducing toxicity of methotrexate with folic acid].

Authors:  P Harten
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

4.  Isolated thrombocytopenia associated with low dose methotrexate therapy.

Authors:  G Lapadula; C De Bari; C A Acquista; F Dell'Accio; M Covelli; F Iannone
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

Review 5.  Should folate supplementation be routinely recommended for older patients receiving methotrexate?

Authors:  B F Leeb
Journal:  Drugs Aging       Date:  1994-11       Impact factor: 3.923

6.  Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis.

Authors:  G Bolla; P Disdier; J R Harle; D Verrot; P J Weiller
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

7.  Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.

Authors:  T Dervieux; D Furst; D O Lein; R Capps; K Smith; J Caldwell; J Kremer
Journal:  Ann Rheum Dis       Date:  2005-01-27       Impact factor: 19.103

Review 8.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 9.  Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials.

Authors:  Kathleen M M Vanni; Houchen Lyu; Daniel H Solomon
Journal:  Rheumatology (Oxford)       Date:  2020-04-01       Impact factor: 7.580

10.  A case of pancytopenia secondary to low-dose pulse methotrexate therapy in a patient with rheumatoid arthritis and renal insufficiency.

Authors:  G T Park; D W Jeon; K H Roh; H S Mun; C H Lee; C H Park; K W Kang; S M Kim; J M Kang; H C Park
Journal:  Korean J Intern Med       Date:  1999-01       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.